As an investor, staying informed about a company’s earnings history is essential for making well-informed investment decisions. In the case of Illumina, a leading company in the genomics industry, understanding its earnings history can provide valuable insights into its financial performance and growth trends.
Illumina is listed on the Nasdaq stock exchange under the stock symbol ILMN, making it easily recognizable for investors. Being listed on Nasdaq offers visibility and credibility to the company, attracting potential investors who are interested in the biotechnology industry.
While the specific upcoming earnings date for Illumina is not currently available, analyzing past earnings report dates can help investors estimate when the next earnings report may be released. By identifying patterns and trends in the historical reporting dates, investors can prepare themselves for future announcements.
- Illumina is listed on the Nasdaq stock exchange under the stock symbol ILMN.
- Investors can estimate the upcoming earnings report date by analyzing past earnings report dates.
- Understanding Illumina’s earnings history provides insights into its financial performance and growth trends.
- The company’s strong presence in the biotechnology industry makes it an attractive investment option.
- Stay updated on Illumina’s earnings and stock performance to assess its growth potential and make informed investment decisions.
Illumina Stock Symbol and Listing
When it comes to investing in Illumina, knowing its stock symbol and listing can provide valuable insights. Illumina is listed on the Nasdaq stock exchange under the stock symbol ILMN. Being part of the Nasdaq exchange offers several advantages for the company.
Disclaimer: This website offers generic information about individuals, brands, and businesses for entertainment and satire purposes. It does not provide financial advice or serve as an authoritative source. Content is based on various online sources and may be outdated or incorrect due to time and industry changes. Visitors should verify information independently and seek professional advice for decisions. All images are for visual demonstration only and do not represent real products or individuals. This site may earn an affiliate commission if any links are clicked on.
Firstly, Nasdaq is one of the largest stock exchanges globally, providing visibility and credibility to companies listed on its platform. This listing gives Illumina exposure to a wide range of potential investors and enhances its market reputation.
Secondly, the stock symbol ILMN makes it easy for investors to identify and track Illumina’s stock performance. Whether you are a seasoned investor or new to the market, having a recognizable stock symbol simplifies the process of researching and monitoring the company’s stock.
Investing in ILMN stock can be an opportunity to gain exposure to the biotechnology industry’s growth potential and Illumina’s innovative solutions. Stay informed about Illumina’s stock symbol and keep an eye on its listing on the Nasdaq exchange to make informed investment decisions.
Illumina Earnings Date
Investors eagerly await the upcoming earnings report from Illumina (ILMN). While the specific earnings date is not yet available, investors can rely on historical reporting patterns to estimate when the next earnings report will be released.
By analyzing the past earnings report dates of Illumina, investors can identify patterns and trends that provide insights into the company’s financial performance. This analysis allows investors to anticipate the estimated earnings date and be prepared for any potential market impact.
Staying informed about the estimated earnings date is crucial for investors who want to make timely investment decisions. The earnings report provides valuable information about Illumina’s financial health, growth prospects, and overall market sentiment towards the stock.
To better visualize the historical earnings dates of Illumina, take a look at the table below:
|Earnings Per Share (EPS)
|May 4, 2021
|February 11, 2021
|October 29, 2020
|July 30, 2020
Illumina Earnings History
Illumina Earnings Announcement Details
In the previous quarter, Illumina reported earnings of $0.33 per share, surpassing the Zacks Consensus Estimate of $0.13 per share. This exceptional performance led to a positive earnings surprise of 153.85%, highlighting the company’s strong financial performance.
These impressive earnings per share indicate that Illumina has outperformed market expectations, demonstrating its ability to generate substantial profits and deliver value to its shareholders. This positive financial outcome reflects the company’s effective strategies and successful execution of its business plans.
The substantial earnings surprise not only reflects Illumina’s profitability but also underscores its position as a market leader in the biotechnology industry. Investors can have confidence in the company’s ability to continue driving growth and creating value in the future.
Illumina’s remarkable financial performance in the previous quarter is a testament to its strategic initiatives, innovative products, and strong market presence. As the company continues to leverage its expertise in genomics solutions, investors can anticipate significant growth opportunities and enhanced shareholder value in the long run.
Illumina Revenue and Financials
Illumina, a prominent player in the biotechnology industry, has showcased its potential for growth through its annual revenue and financial performance. As of the latest financial report, Illumina has recorded an impressive annual revenue of $4.58 billion, firmly establishing its market presence. This revenue figure reflects the company’s ability to generate substantial sales and underscores its position as a key player in the genomics solutions market.
However, it is important to note that Illumina’s net income over the last four quarters has been -$4.40 billion. This negative net income indicates that the company’s expenses have outpaced its revenue during this period. Investors should consider this financial aspect when evaluating Illumina’s investment potential and its ability to generate sustainable profits in the future.
One key metric that investors often analyze is the price-to-earnings (P/E) ratio. The P/E ratio helps evaluate a company’s valuation relative to its earnings by comparing the market price per share to the company’s earnings per share. It provides insight into how the market values the company’s earnings and growth prospects.
Price-to-Earnings (P/E) Ratio Calculation for Illumina:
To calculate the P/E ratio for Illumina, we need to divide the market price per share by the company’s earnings per share. Let’s assume the market price per share for Illumina is $200, and the company’s earnings per share is $5. The P/E ratio would be calculated as follows:
|Market Price per Share
|Earnings per Share
|Price-to-Earnings (P/E) Ratio
In this example, the P/E ratio for Illumina would be 40. A higher P/E ratio indicates that the market has higher expectations for the company’s earnings growth, while a lower P/E ratio suggests more conservative expectations.
It is essential for investors to carefully analyze Illumina’s financial performance, annual revenue, net income, and price-to-earnings ratio to make informed investment decisions. While the company’s annual revenue highlights its market presence and growth potential, the negative net income raises concerns about its profitability. Evaluating the price-to-earnings ratio can provide further insights into market expectations and valuation.
Illumina Earnings Call and Investor Relations
Stay updated on Illumina’s financial performance and strategic initiatives by participating in the company’s earnings call. This interactive session allows investors to listen to discussions about the latest earnings report, gain a deeper understanding of Illumina’s financials, and ask questions directly to company executives.
Illumina’s commitment to investor relations extends beyond the earnings call. The company recognizes the importance of keeping shareholders well-informed and provides regular updates on its operations, financial results, and market insights. Through various communication channels, including press releases, annual reports, and investor presentations, Illumina strives to foster transparency and foster strong relationships with its investors.
Investors can rely on Illumina’s comprehensive investor relations resources to access financial statements, historical earnings data, and other relevant information. By staying informed about Illumina’s financial performance and strategic initiatives, investors can make well-informed investment decisions and evaluate the company’s growth potential.
Illumina Analyst Estimates and Ratings
When considering investment opportunities, it is essential to assess the potential future performance of Illumina (ILMN). Analyst estimates and ratings provide valuable insights into the company’s financial performance and market expectations. Let’s delve into these key factors that can influence investment decisions.
Analyst estimates offer forecasts for Illumina’s financial performance, helping investors gauge the company’s growth trajectory. These estimates take into account various factors, such as revenue projections, earnings per share, and market trends. By analyzing analyst estimates, investors can gain valuable insights into Illumina’s potential in the biotechnology industry.
Analyst ratings reflect how industry experts view Illumina’s stock as an investment opportunity. These ratings are based on various factors, including financial performance, strategic initiatives, and market conditions. Investors can use analyst ratings to assess the suitability of Illumina’s stock for their investment portfolio.
It is important to note that analyst estimates and ratings are subjective opinions based on available information. Investors should conduct thorough research and consider multiple sources of information before making any investment decisions.
Illumina Analyst Estimates Comparison
|EPS Estimate (Current Quarter)
|EPS Estimate (Next Quarter)
|EPS Estimate (Current Year)
|EPS Estimate (Next Year)
The table above presents a comparison of Illumina’s analyst estimates with estimates from two industry analysts. These estimates demonstrate the range of expectations for the company’s earnings per share (EPS) for the current and next quarters, as well as the current and next fiscal years. It is important for investors to consider these differing perspectives when evaluating Illumina’s potential financial performance.
By examining analyst estimates and ratings, investors can gain valuable insights into Illumina’s potential and make informed investment decisions. Alongside thorough analysis and consideration of other factors, these evaluations provide a comprehensive view of the company’s financial performance and market expectations.
Illumina’s Impact on the Biotechnology Industry
Illumina, a leading player in the biotechnology industry, has revolutionized the field with its innovative genomics solutions. Through its advancements in genomic sequencing and analysis, Illumina has paved the way for groundbreaking discoveries and transformed the landscape of medical research.
With its state-of-the-art technologies and platforms, Illumina has empowered researchers and scientists to unlock the mysteries of the human genome. By providing efficient and accurate sequencing capabilities, the company has enabled rapid advancements in personalized medicine, genetic testing, and disease diagnostics.
One of the key contributions of Illumina to the biotechnology industry is its ability to generate vast amounts of genomic data, allowing researchers to delve deeper into the intricacies of human genetics. This wealth of information has opened up new avenues for understanding diseases, identifying potential therapeutic targets, and developing targeted treatments.
Furthermore, Illumina’s genomics solutions have not only impacted the healthcare sector but also influenced various other industries. Its applications extend to areas such as agriculture, conservation, and forensic science, facilitating advancements in crop improvement, biodiversity preservation, and criminal investigations.
As a result of its groundbreaking technologies and comprehensive solutions, Illumina has played a crucial role in driving the growth and progress of the biotechnology industry as a whole. Its products and services have become indispensable tools for researchers, healthcare professionals, and companies working towards a better understanding of the human genome and its implications.
In the next section, we will explore the financial aspects of Illumina’s journey, including its earnings report and market performance.
Investors looking to make well-informed investment decisions should closely monitor Illumina’s earnings report, as it provides valuable insights into the company’s financial performance and growth prospects. By staying updated on Illumina’s earnings history and analyzing its stock performance, investors can assess the company’s potential for long-term success in the biotechnology industry.
With the stock symbol ILMN and its listing on the Nasdaq exchange, Illumina offers visibility and credibility to potential investors. The company’s strong financial performance, demonstrated by positive earnings surprises and a substantial annual revenue, further supports its investment potential.
Moreover, Illumina’s innovative genomics solutions have had a significant impact on the biotechnology industry, creating opportunities for medical research, personalized medicine, and genetic testing. As Illumina continues to advance in the genomics space, investors can consider the company’s growth potential when making strategic investment decisions.
What is Illumina’s stock symbol?
Illumina is listed on the Nasdaq stock exchange under the stock symbol ILMN.
When is Illumina’s earnings report date?
The specific upcoming earnings date for Illumina is not currently available, but investors can rely on historical reporting dates for an estimate.
What was Illumina’s previous earnings per share?
In the previous quarter, Illumina reported earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.13 per share.
How did Illumina perform in terms of earnings surprise?
Illumina’s earnings report reflected a positive earnings surprise of 153.85%, showcasing the company’s strong financial performance.
What is Illumina’s annual revenue?
Illumina has recorded an annual revenue of $4.58 billion, demonstrating its market presence and potential for growth.
What is Illumina’s net income over the last four quarters?
Illumina has a net income of -$4.40 billion over the last four quarters. Investors should consider this financial data when evaluating the investment potential of Illumina.
Does Illumina offer an earnings call for investors?
Yes, Illumina offers an earnings call that allows investors to listen to discussions about the latest earnings report and gain deeper insights into the company’s financial performance.
How does Illumina prioritize investor relations?
Illumina prioritizes investor relations by providing regular updates and resources to keep shareholders well-informed.
How do analyst estimates and ratings impact Illumina’s investment potential?
Analyst estimates provide forecasts for Illumina’s financial performance, while ratings indicate how analysts view the stock’s suitability as an investment at a given time.
What impact has Illumina made on the biotechnology industry?
Illumina’s innovative genomics solutions have made a significant impact on the biotechnology industry, opening up new possibilities for medical research, personalized medicine, and genetic testing.
Disclaimer: The information presented on this site, including assessments of individuals' wealth, company history, or any other content, is derived from publicly available data and confidential insights shared by individuals or their authorized representatives. While we endeavor to maintain the highest level of accuracy in our assessments, unless explicitly stated otherwise, these valuations are approximate and all information may be outdated or simply an estimate. It's important to view all information as for entertainment and satirical purposes. This site may earn an affiliate commission if any links are clicked on. We appreciate any corrections, removal requests, or feedback, which can be submitted through the contact form link at the bottom of this page.